Vaxcyte vs Spyre Therapeutics
Vaxcyte (PCVX), health care, and Spyre Therapeutics (SYRE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Vaxcyte is worth $9.4B on the stock market and Spyre Therapeutics $8.9B: Vaxcyte is valued at 6% more. Over the past year Vaxcyte's share price has moved +24.4% and Spyre Therapeutics's +312%.
Key facts
- Vaxcyte market value
- $9.4B
- Spyre Therapeutics market value
- $8.9B
- Spyre Therapeutics revenue
- $0FY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Vaxcyte | Spyre Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $9.4Bhigher | $8.9Blower |
| Revenue | — | $0 |
| Earnings | -$766.6Mlower | -$155.2Mhigher |
| Employees | 507higher | 130lower |
| Total assets | $3Bhigher | $777.8Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | — | — |
| P/B | 3.6lower | 9.3higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | — |
| Balance sheet | ||
| Net assets | $2.7Bhigher | $715.2Mlower |
| Total liabilities | $317.2Mhigher | $62.5Mlower |
| Total debt | — | — |
| Cash on hand | $174Mhigher | $85.7Mlower |
| Price change | ||
| Today | -3.59%higher | -5.60%lower |
| 1 year | +24.4%lower | +312%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Vaxcyte only (2)
- Peter Kolchinsky5.8%
- Lee Ainslie0.8%
Spyre Therapeutics only (1)
- Brandon Haley0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns PCVX · Who owns SYRE
More on Vaxcyte
Further comparisons
Vaxcyte against its closest peers
Spyre Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Vaxcyte or Spyre Therapeutics?
By market value, Vaxcyte is the larger: $9.4B against $8.9B for Spyre Therapeutics.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Vaxcyte and Spyre Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Vaxcyte and 1 holds Spyre Therapeutics.
Cite this page
Funkfolio, “Vaxcyte vs Spyre Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/pcvx-vs-syre
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.